Burzynski Research Institute Inc (BZYR) Stock Price & Analysis
Burzynski Research Institute Inc (BZYR) rose 0.00% to USD 0.01 as of July 26, 2026 at 02:10 UTC, according to Nexqual real-time market data.
BZYR last closed at USD 0.01; the session ranged USD 0–0 on volume of 5,103 shares. Market capitalization is $788,690, with a 52-week range of USD 0–0.05 (PNK). Source: Nexqual, July 26, 2026 at 02:10 UTC.
Key Statistics (as of July 26, 2026 at 02:10 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.01 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.05 |
| Volume | 5,103 shares |
| Market Cap | $788,690 |
| Exchange | PNK |
Technical Analysis (BZYR)
Nexqual's technical model rates BZYR "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 26, 2026 at 02:10 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.45 (neutral) |
| vs SMA50 | Below (USD 0.01) |
| MACD | -0 (negative) |
Analyst Ratings (BZYR)
Wall Street analysts rate BZYR "None", per Nexqual as of July 26, 2026 at 02:10 UTC.
| Consensus Rating | None |
|---|
Earnings (BZYR)
Source: Nexqual, July 26, 2026 at 02:10 UTC.
Financials & Fundamentals (BZYR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.03 |
| Total Cash | $2,165 |
| Total Debt | $0 |
| Free Cash Flow | $224,833 |
Source: Nexqual, July 26, 2026 at 02:10 UTC.
Financial Health Score (BZYR)
Nexqual rates Burzynski Research Institute Inc's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 02:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $2K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$258K |
| Efficiency | Mixed — No data |
Ownership (BZYR)
| Insider Ownership | +81.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 131.45M |
| Float | 24.97M |
Source: Nexqual, July 26, 2026 at 02:10 UTC.
Leadership (BZYR)
Burzynski Research Institute Inc is led by Stanislaw R. Burzynski (age 82), President, CFO, Company Secretary, Principal Finance & Accounting Officer, CEO and Chairman, per Nexqual as of July 26, 2026 at 02:10 UTC.
| President, CFO, Company Secretary, Principal Finance & Accounting Officer, CEO and Chairman | Stanislaw R. Burzynski (age 82) |
|---|---|
| Vice President of Clinical Trials | Tomasz Janicki (age 59) |
From Burzynski Research Institute Inc's Latest SEC 10-K Filing (filed 2025-05-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers.
- The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARNI | ARNO THERAPEUTICS INC | USD 0 | ▲ 0% |
| PKTX | ProtoKinetix, Inc. | USD 0.01 | ▲ 3.12% |
| HSTC | HST Global, Inc. | USD 0.7 | ▲ 0% |
| MYMX | MYMETICS CORPORATION | USD 0 | ▲ 0% |
| FPMI | FLUOROPHARMA MEDICAL INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 02:10 UTC. This page is informational and not investment advice.